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issues relating to adherence to topical glaucoma 
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Purpose: Investigating patients’ perceptions of their illness can provide important insights 
into the experience and management of the illness and associated treatment, and enhance 
understanding of variations in adherence to prescribed medication. The Common-Sense Model 
of Self-Regulation (CSM) provides a theoretical framework for the study of illness cognitions, 
health behavior, and adherence to health recommendations. The aim of this study was to use the 
CSM to investigate the experience of glaucoma and its treatment from the patients’ perspective, 
and to apply these insights to classify and clarify issues related to nonadherence with treatment.
Patients and methods: A qualitative investigation using semi-structured interviews took place 
in two outpatient glaucoma clinics. Thirty-three patients with primary open-angle glaucoma 
using hypotensive eye drops participated in the study. Deductive content analysis was used to 
analyze the interview data.
Results: Issues relating to nonadherence with hypotensive eye drops and patients’ experience 
with their glaucoma and treatment were identified. Treatment schedule and patient factors were 
classified as common barriers to adherence. Further themes include experienced symptoms 
of glaucoma, illness coherence, and the emotional and practical consequences of the illness.
Conclusion: Findings provide important insights into the emotional and practical outcomes 
of glaucoma for patients, perceived symptoms of the illness, and insights into patient memory 
and cognition. These findings provide supporting evidence for the importance of conducting 
theoretically driven qualitative investigations of patients’ experience with glaucoma and their 
treatment, and provide suggestions on key issues that need to be addressed in future multidi-
mensional interventions aimed at improving adherence and patient quality of life.
Keywords: glaucoma, adherence, patient experience, qualitative research, Common-Sense 
Model of Self-Regulation
Introduction
Glaucoma is the second most common cause of registered blindness in the UK1 and 
a major cause of blindness worldwide, with an estimate of 79.6 million people to be 
affected by glaucoma by 2020.2 Glaucoma is a pressure-related optic neuropathy; 
currently the only treatable risk factor for glaucoma is increased intraocular pressure 
(IOP).3,4 In the majority of patients IOP can be lowered to prevent or slow further 
vision loss with the use of hypotensive eye drops.5,6 While the efficacy of antiglau-
coma medications is established, a significant proportion of patients prescribed these 
drops do not adhere to their treatment regimen.7 Nonadherence to treatment affects the 
individual, in terms of disease progression and visual disability, as well as society with 
valuable resources required to pay for unused medications and additional interventions 
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to achieve disease control, along with support for those with 
preventable glaucoma-related disability.8,9
The majority of studies in the literature investigating 
the antecedent factors relating to adherence to glaucoma 
treatment have employed a quantitative methodological 
approach,10–12 with fewer studies, by comparison, adopting 
a qualitative approach.13–16 A qualitative approach allows 
for an in-depth analysis of patient experience and provides 
a method for identifying concerns and needs that are not 
always evident from quantitative methods.17,18 While previ-
ous qualitative research has identified factors relating to 
nonadherence with glaucoma treatment, one of the critiques 
in the literature is the lack of sufficient theory-driven investi-
gations to inform patient-centered interventions, which aim 
to enhance adherence.19–21 Health behavior theories provide 
evidence-based insights of key determinants of behavior.22 
Research has shown that developing a theoretical understand-
ing of factors that influence behavior, and the underlying 
mechanisms of this process, is essential in the design and 
implementation of effective interventions of behavior change 
to target those factors.22–24 The use of a qualitative method of 
inquiry offers researchers the means to explore how prespeci-
fied theory-based influences of behavior are experienced and 
construed by patients.
The Common-Sense Model of Self-Regulation (CSM) 
provides a theoretical framework for the study of individuals’ 
illness representations (or illness perceptions) and how these 
may guide the adoption of coping strategies to manage their 
illness.25 According to the CSM, individuals form a cogni-
tive representation of a health threat, which consists of the 
following five dimensions: identity, consequences, cause, 
timeline, and cure/control.26 Identity reflects perceived 
symptoms and illness label. Consequences relate to beliefs 
regarding the impact of the illness on a person’s life. Timeline 
is the perceived duration of the illness. Cause is defined as 
individuals’ beliefs relating to causal factors of the illness. 
The cure/control dimension reflects beliefs about whether the 
illness can be cured or controlled.26 This has subsequently 
been divided into personal control, to reflect beliefs relating 
to the controllability of the illness by the individual’s actions, 
and treatment control associated with beliefs regarding 
the effectiveness of treatment in controlling or curing the 
illness.27 A sixth dimension, illness coherence representing 
individuals’ understanding of their illness, was also included 
thereafter in measures of illness perceptions (eg, the Revised 
Illness Perception Questionnaire).27 Individuals also form 
emotional representations, in a parallel process, which 
reflect affective reactions to the health threat.28 Cognitive 
and emotional representations guide the adoption of coping 
strategies to manage the illness and the emotional response to 
the illness, and these in turn influence illness and emotional 
outcomes.29 Problem-focused coping strategies, such as treat-
ment adherence, are likely to lead to adaptive outcomes such 
as effective management of the illness, better functioning, 
and quality of life.29 Individuals’ appraisal of the efficacy of 
such coping mechanisms can lead to a modification of illness 
representations.28
The CSM is regarded as a dominant theoretical model in 
explaining health outcomes and providing insights into how 
individuals manage a chronic illness in their everyday life;25,28 
and studies have shown associations between patients’ ill-
ness perceptions and adherence to treatment.30 However, 
only a limited number of studies have investigated illness 
perceptions in relation to medication adherence in patients 
with glaucoma,19,31,32 and these have utilized a quantita-
tive methodological approach. The present study extends 
previous research and adds to the available literature by 
closely adhering to the CSM as a theoretical framework to 
guide the investigation. Using the CSM provides the basis 
to explore how illness perceptions, which have previously 
been shown to affect adherence, are construed by patients 
with glaucoma through their narrative of their experience 
with glaucoma and prescribed treatment. Adopting the CSM 
enables the identification of factors that are potentially modi-
fiable, such as illness representations or perceived barriers, 
which could be targeted to enhance adherence to treatment.33 
The application of the CSM to these issues will contribute 
to formative research that will inform the development of 
multidimensional interventions to improve medication adher-
ence in patients with glaucoma. Interventions designed to 
change patients’ perceptions of their illness have been asso-
ciated with positive health outcomes and improved adher-
ence to treatment.34,35 The emphasis on theory in the present 
study means that we are able to provide recommendations 
of interventions that are grounded in theory. The primary 
aim of our study was to explore patients’ perceptions and 
experience of their glaucoma and treatment regimen, and 
how these cognitions may relate to variations in adherence 
to treatment. We adopted innovative methods to provide a 
comprehensive, detailed description of factors contribut-
ing to medication adherence in patients with glaucoma. 
We present thematic maps of patients’ experience with their 
illness and treatment based on dimensions of the CSM and 
taxonomies identified in the literature in regard to barriers 
to adherence.13–16 A further aim was to provide suggestions 
of appropriate interventions, based on our findings, and to 
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identify issues, which may require further investigation. 
As this is a qualitative investigation, we do not report specific 
hypotheses, but expect dimensions from the CSM to feature 
in the data, offering key insights of patients’ perceptions and 
experience with their illness.
Materials and methods
ethics
Ethical approval for the present investigation was granted 
by the NHS Nottingham Research Ethics Committee 2 
(Reference: 10/H0408/38). Written informed consent was 
obtained from all patients taking part in the study prior to 
data collection. Participants were informed that they could 
withdraw from the study at any point during the interview. All 
patients providing consent participated fully in the interview 
and their data were included in the analysis.
interview schedule
The interview schedule was based on the Brief Illness Percep-
tion Questionnaire,36 a validated measure of patients’ illness 
perceptions across a number of illnesses. The questions were 
designed to capture patients’ views and experiences relating 
to the identity of the illness, perceived consequences, cure/
control, illness coherence, and emotional representations. 
These were supplemented with additional questions concern-
ing patients’ self-reported adherence to treatment and issues 
with treatment regimen, which were informed by prior litera-
ture. Five general questions were included in the schedule 
(Table 1). For each question, additional probing questions 
were prepared prior to the study to clarify patients’ responses 
and to provide a detailed account of their experience with 
their illness. All interviews were conducted by the same 
researcher, and these lasted ~20 minutes.
Analysis protocol
Thirty interviews were audio-recorded and transcribed 
verbatim; for the remaining three interviews, notes were taken 
of participants’ narratives during the interview, and these 
were used in the analysis. Interview transcripts were imported 
into the NVivo8 software,37 a program for organizing data 
in order to conduct qualitative content analysis.38 Deductive 
content analysis was adopted, which involves the analysis 
of patients’ transcribed accounts driven by a theoretical con-
struct (ie, the CSM) and previous findings in the literature.13–16 
This comprised three phases: preparation, organizing, and 
reporting of the analysis and findings.38 These are described 
below and the resulting content categories and derived themes 
are presented in the form of thematic maps (Figures 1–3).
Preparation phase
The preparation phase involved the reading of transcripts 
before starting the analysis.
Organizing phase
This phase involved classifying text from the interview 
transcripts into content categories in order to develop themes 
relating to our research question. This took the form of a top-
down process. The CSM dimensions and findings from previ-
ous literature investigating patient experience and adherence 
with glaucoma treatment were used to guide the development 
of categories. Patients’ responses were then reviewed to 
identify key words of short phrases, which were coded on the 
Table 1 interview schedule
Questions Prompts
1. From your experience, what do you 
think the symptoms of glaucoma are?
·	 have you experienced any of these symptoms?
2. What have you learnt from this 
experience?
·	 Prophylaxis
·	 Do you feel it is important to take your medication as prescribed? Why/why not?
·	 Any issues with the treatment schedule?
3. how do you feel about using your 
eye drops?
·	 if patients mentioned development of a routine to help them take their eye drops, they were asked 
to specify the nature of the routine
·	 self-administration of eye drops or help from others?
·	 how often do you miss your drops? Occasionally/often/never
·	 reasons for using/not using eye drops, if a patient suggests that they are adherent/nonadherent
4. What are the consequences of your 
glaucoma on your daily life, if any?
·	 Prevents you from carrying out certain tasks that would otherwise be possible?
·	 Does it affect you emotionally?
·	 negative consequences of further vision deterioration/vision loss?
5. how has your life changed after being 
diagnosed with glaucoma?
·	 For better (awareness) or worse (obstacles to face in daily life)?
Note: Interview schedule with five predetermined questions and prompts associated with each question.
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basis of the developed categories. Manifest coding was used, 
meaning that patients’ exact responses were coded. Codes 
were then assigned to each relevant category. For example, 
in regard to the “identity of the illness”, patients’ narratives 
revealed the experience of symptoms that were attributed to 
glaucoma, such as blurred vision and sensitivity to bright 
lights (codes). These codes that reflected a change in patients’ 
vision were grouped, together with similar others, into the 
category of “change in vision”. The frequency of occurrence 
of the identified categories was counted once per transcript, 
rather than how many times a specific code was seen in a 
specific interview transcript.
Categories were reviewed and refined to ensure that 
there was no overlap and to assess whether two or more 
categories could be integrated when frequency of occurrence 
in the transcripts was low. This process also enabled the 
researchers to identify underlying psychological concepts 
linking several categories together in order to derive themes 
of patients’ narratives. Themes were developed by grouping 
categories together based on their content and meaning in 
relation to the research question. Depending on the nature 
of the categories, some of the identified themes had associ-
ated subthemes linked to them, and these were organized 
in a hierarchy.
The resulting themes and their associated subthemes 
and categories were verified by an independent rater to 
ensure reliability.39 Results showed substantial agreement 
between the researcher and the independent rater (κ=0.74, 
P,0.001).
reporting phase
Following the identification of categories, subthemes, and 
themes, thematic maps were developed to illustrate the con-
tent and nature of the relationship between them. 
?????????????????????
?????????????????? ?????????????????????????????????????????????????
???????????????
?????? ???????????????????????????????????????????????????????????????????????????????????
?????????? ?????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????
????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????
????? ????????? ?????????? ?????
Figure 1 Thematic map featuring “barriers to adherence”.
Note: n represents the number of interview transcripts containing the specified codes.
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open-angle glaucoma requiring treatment with hypotensive 
eye drops. Patients reported taking antiglaucoma medications 
for an average of 7 years (range: 1 month to 20 years). Nine 
patients reported having undergone glaucoma-related surgery.
Four themes were developed, which explained patients’ 
beliefs and experience with their illness and treatment: 1) barri-
ers to adherence, 2) symptoms of glaucoma, 3) consequences of 
glaucoma, and 4) illness coherence. These are presented below, 
together with selected quotations from the interview transcripts.
Barriers to adherence
Two subthemes were developed under the theme of barriers 
to adherence, which illustrate common obstacles that patients 
face, which may prevent them from taking their eye drops as 
prescribed. These were treatment schedule and patient factors 
(Figure 1). The rationale for this was that issues with treatment 
and issues to do with patients’ lifestyle, motivation, and health 
beliefs (under patient factors) were factors associated with barri-
ers to adherence, and this is supported by previous literature.13,16
Treatment schedule
Treatment schedule refers to difficulties experienced by 
patients, which may prevent them from taking their eye 
??????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????
????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????????????????
Figure 2 Thematic map of “symptoms of glaucoma”.
Notes: The theme “symptoms of glaucoma” consists of four categories: “change 
in vision”, “change in the physical appearance of the eyes”, “experience of pain in 
the eyes”, and “no reported symptoms”. n represents the number of interview 
transcripts containing the category-relevant codes.
???????????????????????????????
????????????????????????????????????????????????
??????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
?????????????????????????
???????????????????????????????????????????????
??????????????????????
Figure 3 Thematic map featuring “consequences of glaucoma”.
Notes: The theme “consequences of glaucoma” was described by two subthemes, “practical consequences resulting from potential vision loss” and “emotional consequences”, 
and their associated categories, as identified in patients’ interviews. n represents the number of interview transcripts containing the category-relevant codes.
Results
Thirty-three patients (20 males, 13 females) with an aver-
age age of 70.7 years (SD =12.32; range: 31–90 years) took 
part in the study. Inclusion criteria included having visual 
acuity .6/12 and a diagnosis of ocular hypertension or primary 
Patient Preference and Adherence 2019:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
824
McDonald et al
drops as prescribed. The majority of patients reported not 
experiencing any issues with their treatment schedule, while 
a number of patients found the eye drops inconvenient to use 
(n=10). This was related to design issues of the bottles, the 
number and frequency of drop application, as well as having 
other competing tasks that clashed with the time of day that 
patients had to take their medication. One patient reported 
“They are not easy to put in, they have me an eye drop stopper 
but it floods your eye going in, there’s more than is intended” 
(male, 70). Other patients mentioned “… it’s inconvenient 
when you have to do it four times a day and if you have to 
go out for the day and you don’t take your drops with you 
…” (female, 75) and “[some eye drops] are supposed to be 
kept in the fridge which is deeply inconvenient if you are 
out somewhere…” (male, 69). Patients also reported the 
experience of medication side effects, such as stinging of 
the eyes or blurred vision.
Patient factors
This refers to issues related to patients’ beliefs regarding 
their illness and treatment, and their ability to adhere with 
treatment. Four categories were developed that were directly 
related to patient factors: memory, based on self-reported 
prior adherence, routine/organizational skills in taking the 
eye drops, motivation, and health beliefs.
In regard to memory issues, one third of the patients 
reported having good memory, in that they reported never 
having missed doses since they were prescribed the medica-
tion. However, the majority of patients (n=17) reported that 
they would forget to take their eye drops, and this ranged from 
occasionally forgetting to often forgetting to take medica-
tion as prescribed. A number of patients mentioned in their 
narrative that they would routinely take them as prescribed, 
while some patients (n=9) specified the development of a 
system or routine in taking their eye drops, as a device to 
improve adherence. For example, as one participant stated, 
“I routinely do it last thing at night like cleaning my teeth, 
preparing for bed…” (male, 65). Taking drops was linked 
with food preparation and activities, which acted as reminders 
to take their eye drops at certain times of the day. As one 
patient mentioned, other strategies to aid memory included, 
“… I make columns in my notebook so I make sure I don’t 
miss them” (female, 76).
A further category of patient factors was motivation in 
taking the eye drops. Patients reported that they took their 
eye drops to reduce eye pressures. Patients also reported that 
they believed that it was important to take their eyes drops 
in order to prevent loss of vision. As one patient mentioned, 
“I feel I’ve got no choice, if I don’t take them I feel I’ll go 
blind…” (male, 70). Social pressure, in terms of doctors 
checking eye pressures and family members reminding 
patients to take their eye drops, were reported to motivate 
patients to take their eye drops.
Health beliefs, such as personal control and treatment 
control, were also identified in the interview transcripts. 
In line with the CSM of self-regulation, treatment control 
was conceptualized as patients’ perceptions of the efficacy 
of their treatment in controlling their glaucoma. Patients who 
stated explicitly in their interview that they felt that their 
treatment was effective in lowering their eye pressures or 
preventing further vision deterioration, for example, were 
seen as having higher treatment control (n=7). For example, 
one patient reported “… since I started putting drops in my 
vision to me is perfect … they’ve absolutely done me good 
that’s all I can say” (male, 83), while another commented “… 
it’s necessary to bring the pressure down … they found this 
medication to counteract the pressure and in doing so it’s for 
my betterment” (male, 65).
Three patients, however, reported losing faith in their 
eye drop efficacy (reflecting lower treatment control). 
They felt that their medication failed to lower their eye pres-
sures sufficiently, which, for the majority of these patients, 
resulted in surgery. One patient reported, “the drops stopped 
working … that’s why they needed to do the operation … 
I was curious as to why I need to keep taking them if they are 
not actually working…” (male, 31). Another patient stated, 
“I don’t see how they can be effective in my personal experi-
ence, if I don’t use the drops for two weeks I don’t notice a 
significant change in my vision” (female, 51).
Personal control, reflecting patients’ beliefs in whether 
they can control or manage their illness, in terms of taking 
medication as prescribed, was observed in the data. One third 
of patients reported that they felt confident that they could 
administer their eye drops to control their illness, reflecting 
higher perceived personal control over their illness. Some 
patients reported that they relied on others to administer their 
drops or to remind them to take their drops at the right times. 
As one patient reported, “I’m not very good at putting drops in 
myself, so my wife puts my drops in usually; I’m a bit cautious 
with touching my eyes and things like that…” (male, 59).
symptoms of glaucoma
This reflects patients’ experience of symptoms attributed 
to glaucoma during the course of their illness, and as such, 
the identity they ascribed to their illness (Figure 2). A gen-
eral consensus (n=14) in the interviews was that patients 
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experienced change in vision as a result of glaucoma such 
as loss of focus, difficulty in reading distant material, and 
sensitivity to bright lights. A small number of patients (n=3) 
reported that they experienced changes in the physical 
appearance of their eyes as well as pain in the eyes (n=5), 
as a result of glaucoma. Approximately half of the patients 
reported having no glaucoma-like symptoms. Some felt that 
the absence of symptoms indicative of the illness may be a 
factor contributing to nonadherence: “… people are not tak-
ing their drops because there are no symptoms, they don’t 
know that the pressures are up…” (female, 65).
consequences of glaucoma
Patients were asked to describe the potential impact of 
glaucoma on their lives. Perceived consequences of glau-
coma were identified as a theme, as shown in Figure 3. This 
was described in terms of practical outcomes of the illness, 
reflecting both current and future anticipated consequences, 
and emotional consequences of living with glaucoma.
In regard to practical consequences, inability to travel 
as a result of vision deterioration (n=10) was a prominent 
identified code in patient transcripts: “… suddenly you can’t 
drive and take buses … independence …” (male, 70). Other 
patient reports included not being able to see family and 
friends (n=11). Patients also reported that they would miss 
pursuing their hobbies such as reading (n=9), watching TV 
(n=8), watching or participating in sports (n=9), and looking 
after their garden (n=5).
In regard to the emotional consequences of the illness, one 
third of patients mentioned that they were concerned about 
their glaucoma. Worry, anxiety, and loss of confidence were 
commonly reported outcomes. Patients reported “I’m on the 
edge of worrying, sometimes I can’t even sleep at night…” 
(male, 79), “It’s depressing because you can’t see” (female, 
78) and that “It would be traumatic to lose your eye sight…” 
(male, 48). Others reported that they were constantly aware 
of the problem (“… you always have glaucoma at the back of 
your mind…”, female, 66), and some experienced disappoint-
ment and loss of confidence in carrying out daily activities. 
For example, one patient mentioned, “I feel disappointment 
that I have to use the drops…” (male, 73), while another 
commented that “… I don’t really have the confidence now 
to cope with situations on the road” (female, 64).
illness coherence
Illness coherence reflects clarity and level of certainty that 
patients have with their illness, and an overall understand-
ing of their illness and treatment. This was developed from 
responses to questions associated with what patients have 
learnt from their experience of glaucoma, how their life 
changed as a result of their diagnosis, and how they felt about 
using their eye drops.
Results showed that a number of patients expressed 
knowledge or an awareness of the nature of their glaucoma, 
such as for example, increased eye pressures, visual field loss, 
which was associated with their illness, as well as knowl-
edge of the function of prescribed treatment. The illness 
coherence theme was developed by coding transcripts with 
explicit detail on the nature of their illness and the function 
of medication. Thus, for patients who were seen as having 
higher illness coherence, there was explicit evidence in their 
narrative of the aforementioned points. Responses included 
“It’s a build-up of pressure at the back of the eyes and dam-
ages nerves which leads to blindness” (male, 64). Similarly, 
another patient reported, “What I’ve learned in all fairness, 
the pressures can be reduced with the drops” (male, 49).
The majority of patients spoke about their illness in 
general terms, or reported that they were unsure as to what 
the illness entailed, or the function of their eye drops, thus 
showing through their narrative, lower illness coherence. For 
example, one patient said “I’m only using them, because I’m 
told to use them … to reduce the strain off my eyes, I’m not 
sure what they meant there is a strain in my eyes” (male, 65). 
A similar issue was raised by another patient: “I was very 
concerned because I don’t know enough about it” (male, 59). 
These findings suggest that exploring patients’ understanding 
of their condition is important to determine possible miscon-
ceptions in relation to the illness or treatment.
Discussion
The present investigation used a dominant theoretical 
framework, the CSM, to develop an assessment of patients’ 
experience with glaucoma that goes beyond a commonly 
used evaluation, and includes a broader range of factors that 
may be related to treatment adherence and quality of life. The 
CSM was also used to organize the findings of this study. This 
study adds to the literature by providing important insights on 
the emotional outcomes of the illness, patients’ perceptions 
of glaucoma-related symptoms and adverse events relating to 
the medication, insights into illness coherence, and memory 
as a key contributor to self-reported nonadherence. This is the 
first study, to the authors’ knowledge, which has attempted 
to link the barriers to adherence with these other factors in 
a coherent and structured way.
Adopting the CSM to guide the current analysis assists 
in informing the development of optimally effective 
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interventions to modify nonadherent behavior. In regard 
to interventions to address issues of adherence in patients 
with glaucoma, a Cochrane review40 concluded that “due to 
inadequate methodological quality and heterogeneity of study 
design we are unable to advocate any particular interventions 
at this time” (p. 2). Further patient-centered interventions 
are needed based on patients’ perceptions of their illness 
and treatment regimen. Findings from the present study 
indicate that interventions to improve adherence should take 
into consideration a comprehensive view of patients’ experi-
ence and illness perceptions. This study identified potential 
multifactorial components that may influence adherence, 
one or more of these may affect a patient, and the strategies 
developed must envelop these different components into a 
comprehensive package of adherence support.
emotional consequences of the illness
A key finding in the present investigation was mood and 
depression as emotional consequences of the illness. When 
patients were asked to report the consequences of their illness, 
findings revealed that a number of patients were emotionally 
affected by the illness. Some patients reported feeling 
depressed, stressed, and worried about their illness. Thus, 
mood and depression emerged as key emotional outcomes 
in the present investigation. This presents a key finding, as 
emotional consequences, such as depression, have previously 
been shown to have an effect on nonadherence to health 
recommendations. A meta-analysis (N=47) investigating 
the relationship between depression and adherence to treat-
ment found that patients with depression were more likely 
to be nonadherent.41 The relationship between depression 
and anxiety, and nonadherence to treatment has also been 
observed in patients with glaucoma.42,43 In fact, studies have 
shown that “even nonclinical levels of depressive symptoms 
can be associated with non-adherence” (p. 2402).44 This sug-
gests that depression must be recognized as a key risk factor 
for poor health and nonadherence to health recommendations. 
The present investigation served to identify these emotional 
outcomes in patients with glaucoma. Interventions aimed at 
improving adherence and quality of life in patients with glau-
coma should include an element to address emotional distress.
Practical consequences of the illness
In addition to emotional consequences, patients also 
expressed their concerns with the practical consequences of 
their illness on their lifestyle and quality of life as a result 
of potential vision loss due to glaucoma; this relates to 
the consequences dimensions of the CSM. Such concerns 
included inability to drive, to see family and friends, and 
pursue their hobbies, among others. It is likely that the 
importance of different aspects of vision loss is different 
between patients. A concern however emerging from the 
interview transcripts was loss of independence because of 
visual failure. This is in the context of an aging population 
when other aspects of aging such as loss of hearing and 
limited mobility may also be affecting patients’ ability to 
maintain their independence. A study investigating views 
of glaucoma patients on their treatment45 identified that 
loss of driving license (rather than blindness) was the most 
important aspect of treatment success for patients. Using the 
information derived from patients’ experiences, concerns and 
lifestyle will allow relevant tailored patient-specific interven-
tions to be generated with health messages that incorporate 
the most important concerns. Such concerns, derived from 
patients’ self-reported experiences (eg, inability to drive, 
read, watch TV, visit family), should be focused on patients’ 
health concerns and used in health messages that would act to 
motivate adherence.46 As such, these would serve as powerful 
motivators to minimize medication nonadherent behavior.
Memory
Barriers to adherence included a range of factors relating to 
treatment schedule and patient-centered issues, which were 
seen as inhibiting factors for adhering to prescribed eye 
drops. The identified barriers to adherence confirm previ-
ous findings.13–16 Perceived barriers are likely part of the 
control dimension of the CSM and, therefore, interventions 
to overcome them are likely to result in better adherence. 
Identifying such issues early on in treatment could enable 
clinicians to offer better education to patients and solutions 
to such issues if necessary. Educating patients to deal with 
commonly reported obstacles and enhancing health beliefs 
associated with the importance of medication can improve 
patient adherence.
In regard to patient factors, the majority of patients 
reported occasionally forgetting to take eye drops, especially 
when faced with competing activities or traveling away 
from home. For some patients, such issues were overcome 
by developing a routine linked with everyday activities 
such as taking medication in combination with meals or 
activities that served as cues. This insight may provide a 
mechanism to improve adherence in other patients if useful 
habit-forming associations can be identified and their role in 
improving adherence developed. Perhaps the assessment of 
patients with glaucoma should include enquiry about their 
routine daily activity to identify if their drop dosing schedule 
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could be incorporated into an already established routine 
and stimulated by a “trigger activity” such as brushing teeth 
and this could be enhanced by ensuring that drops are located 
beside their toothbrush, for example. This could form part 
of implementation intention and action-planning strategies 
aimed at enhancing adherence.47,48
identity of illness
In regard to the perceived identity of illness, commonly 
reported symptoms were changes in vision and physical 
appearance of eyes as well as pain in the eye area. It is 
unlikely that these symptoms are caused by glaucoma per se 
as most patients, unless their IOP is significantly elevated, 
are unaware of their elevated IOP. It is more likely that 
patients are confusing some of the adverse effects of medi-
cation, which may feel like “pressure in the eye” with a true 
sensation of raised pressure. Thus, experiencing these side 
effects may act as a demotivating factor for taking their 
medication, in order to avoid the effects. In such cases, 
awareness of such adverse events would initiate a change in 
medications producing no or less side effects, thus enhancing 
the chance of adherence. Informing the patient on the nature 
of symptoms that they may experience as a result of their 
glaucoma, as well as identifying adverse events, which may 
be side effects from the medication, could help to improve 
adherence to treatment and increase patient quality of life. 
Furthermore, given the absence of symptoms in the majority 
of patients with glaucoma, other techniques may be needed 
in this nonsymptomatic group to enhance adherence, such 
as education regarding the risks of nonadherence and the 
benefits of preserving good vision.
limitations
A limitation of the present investigation relates to the small 
sample size used. This was dictated by achievement of theme 
saturation, which is consistent with previous studies using 
qualitative methods. However, the sample selected provided 
an adequate representation of patient experience of glaucoma 
and issues related to treatment.
Conclusion
The present study used a dominant theoretical model in the 
study of treatment adherence, the CSM of Self-Regulation, 
to explore patient-specific parameters, as identified in the 
constructs that patients presented in their interviews, relating 
to how patients represent their illness and how these processes 
may guide decisions relating to treatment. We have also 
used this framework to organize the findings in the form of 
thematic maps. Findings from this investigation guided by 
the CSM can inform the design of future patient-centered 
interventions to overcome patient-specific issues related to 
poor adherence based on patients’ illness perceptions. Fur-
ther, these findings provide supporting evidence of the need 
to conduct theoretically driven qualitative investigations of 
patients’ experience with their illness and treatment, and 
using the identified themes and subthemes to provide recom-
mendations for the development of future patient-specific 
interventions. This study has identified barriers to adherence, 
perceptions of glaucoma-related symptoms and adverse 
events of medications, perceived consequences of the illness, 
and provided insights on what issues need to be addressed in 
a single multidimensional intervention aimed at improving 
adherence to glaucoma treatment and patient quality of life.
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